Vir Biotechnology, Inc.

Securities and Exchange Commission (SEC) for the issuance of debt securities, common stock, preferred stock and warrants from time to time in one or more offerings.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Investments Investments include available-for-sale debt securities and equity investments, which are carried at fair value.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Available-for-Sale Debt Securities The Company s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the unaudited condensed consolidated statements of operations.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The decrease was primarily driven by cost savings from previously announced restructuring initiatives, partially offset by higher clinical expenses from the initiation of our ECLIPSE registrational program for CHD, progression of our oncology programs and an increase in the fair value of contingent payment obligations for our CHD program.

SEC original ↗Vir Biotechnology, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The decrease was largely due to efficiencies and cost savings from previously announced restructuring initiatives.

SEC original ↗Vir Biotechnology, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The decrease was due to the fact that our restructuring initiatives implemented in prior years were substantially completed by the end of 2024.

SEC original ↗Vir Biotechnology, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.

SEC original ↗Vir Biotechnology, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur.

SEC original ↗Vir Biotechnology, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Legal Proceedings 35 Item 1A.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Exhibits 70 Signatures 71 1 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions described in the sections titled Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

SEC original ↗Vir Biotechnology, Inc. — 10-Q Quarterly report10-QAug 5, 2026